SupremeCourt

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Wednesday, February 13, 2013

BMS Hepatitis Patent Invalidated: A Viral Effect for India?

Posted on 11:49 PM by Unknown
In a development with significant ramifications for India, a US district court recently invalidated a pharmaceutical patent covering Baraclude (Entecavir), a leading anti-viral drug for Hepatitis B patients. The drug brings in more than a billion dollars each year for BMS! 

The invalidation was pursuant to a law suit bought by BMS (the patentee) against Teva, a leading Israeli generic company. This drug is of particular interest to India, given a roaring patent contest on this front between BMS and Ranbaxy before the Delhi High Court. However, it bears noting that while the US patent (Number 5,206,244) covers the "parent" or "basic" Entecavir compound, the Indian patent only covers an alleged dosage "improvement". This is owing to the fact that Entecavir is a pre-TRIPS molecule and at the time of BMS's US patent application (in the year 2000), India did not grant pharma product patents.

As the Indian patent specification notes:

"This invention is directed to pharmaceutical compositions containing a low dose of entecavir and the use of such low dose composition to safely and effectively treat hepatitis B virus infection."

The Indian judge refused to grant an interim injunction  to BMS at the first instance, noting that the patent was “vulnerable”. The case has since been posted for "trial", and as I understand it, evidence is currently being recorded. For those interested, the Indian patent number is 213457 and the case details are: Bristol-Myers Squibb Company v. Ramesh Adige & Anr (Ranbaxy) C.S. (O.S) No. 534 of 2010.
 
As I’ve advocated here, in all cases where there is a strong challenge to the patent (which is in 90% of all pharmaceutical patent cases), courts must desist from granting injunctions. Rather, they must dispense with the interim phase and move straight to trial. In most pharmaceutical patent cases at least, this route will ensure that patients and generic manufacturers do not stand to suffer a "bad" patent in the "interim", a suffering that is well beyond "monetary" computation. 

"Working" of Entecavir:

It bears noting that we'd prominently featured Baraclude (Entecavir) in our Form 27 investigation some years ago, showing that "working" statements had not been filed in full for this drug. However, what we gathered is that the drug brought in more than 20 crores for BMS each year. We’ve not reviewed the recent statements by BMS, but assume that there has been better compliance on this front. As Sai Vinod noted recently, the Indian Patent Office (IPO) has again indicated that it is serious about compliance with working statements and Form 27. However, we need to re-examine the "efficacy" of the current format of the Form 27 statement.

For those interested, well known pharma blog, Pharmalot has a good review of the US invalidity decision, as also a link to the text. The decision is interesting for several reasons:  

1. This is not a classic ever-greening case and the drug compound (a carboxy nucleoside analog) is not a mere new form of a known compound. Rather, it is a new compound altogether and was approved by the FDA as an NCE (new chemical entity). To this extent, section 3(d) of the Indian Patents Act will not apply directly to this case.  

2. The US court applied a rigorous obviousness standard and held that although this may be a new compound, it fails the obviousness test since it was essentially an obvious modification of an existing natural compound. The two part analysis can be summarised as below:

i) it would have been obvious to a person skilled in the art to work with the closest known prior art compound (a naturally-occurring nucleoside commonly referred to as "2-CDG") with known anti viral properties.

ii) it would then been obvious to modify the existing compound (2-CDG) by substituting the oxygen atom with a carbon carbon double bond at the sugar portion. A skilled person would have a reasonable expectation that this modification would yield improved antiviral properties.

In other words, although the drug is based on a new compound, the said compound is not patentable, since it was obtained by modifying a known natural substance in a "stock in trade" manner.

The judgment which runs into 170 pages is a wonderful read, with a delightful interspersing of snippets of the cross examination. Sample this:

Tevas counsel: Now, you would agree that if you are looking for conservative changes that could be made, one place you would look at is the periodic table, is that right?
 

Dr Schneller (BMS’ key expert witness): Well, you almost have to, because all molecules are made from elements that are on that periodic table. So there no magic lamp someplace that’s going to come up with new ideas.

Tevas’ counsel: And the periodic table…it’s the chemists’ stock in trade?


Dr Schneller: Yes, sir

An "Alien" Patent Standard in India?
 
This decision helps dislodge the now prevalent presumption that the US almost always reflects “low” patent standards. As this case demonstrates (much like its earlier predecessor Pfizer vs Apotex), US courts do apply a rigororous patentability threshold from time to time. And to this extent, one might actually find that the ostensibly high Indian standards are actually not all that “alien”.

Of course, this is a district court decision and will certainly be appealed to the CAFC (Court of Appeals for the Federal Circuit), reputed to be more "patent friendly". 

One is not certain of the fate of the secondary patent in India. However, one might hazard a guess that, in the light of the "therapeutic efficacy" standard under section 3(d) that now informs most Indian decisions (unless the Supremes alter it in the much awaited Novartis Glivec ruling), BMS' claim to an improved "dosage" regimen is extremely vulnerable.
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in Indian patent litigation, Injunction, obviousness, Pharma, Section 3(d) | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • IPAB on Payyannur Ring
    [*S lightly long post] Background: The Intellectual Property Appellate Board (“ IPAB ”), in its recent order in SubhashJewellery v. Payyan...
  • Guest Post: Intermediary liability in defamation cases - Parle, Mouthshut & Visakha cases to clarify the law
    Chaitanya Ramachandran, who has blogged for us previously over here and here , has sent us this excellent guest post analyzing the extent of...
  • IP Research Assistant position at IIT, Madras
    Feroz Ali Khader, MHRD IP Chair at the Indian Institute of Technology (IIT) Madras, is looking for research assistants to work on various is...
  • Dorling Kindersley v. Sanguine Technical Publishers
    A recent Delhi High Court order passed on 21 January, 2013  with respect to copyright licensing has come to our notice. An analysis of the j...
  • Call for Papers: IIT Bombay and MHRD jointly announce the 2nd International Conference on Management of Intellectual Property and Strategy
    The readers may be interested to know that the Shailesh J. Mehta School of Management of IIT Bombay is geared up to host, in collaboration w...
  • SpicyIP Tidbit: ALCS August Distribution
    In the UK, the Authors' Licensing and Collecting Society is an organization run and owned by writers that collects money due to its mem...
  • Delhi HC rejects the "Hot News" Doctrine: A Summary
    The applicability of the Hot News doctrine was rejected recently in a landmark ruling delivered by Justice Bhat of the Delhi HC. This post i...
  • Satyajit Ray's sketches and copyright controversies
    A copyright row appears to have started between the Satyajit Ray Society and the Delhi Art Gallery, that is organising a countrywide exhibit...
  • Thalappakatti biryani trademark row
    The southern district of Dindigal in Tamil Nadu occupies a special place in the hearts of biryani lovers. In the late 1950s, one Nagasamy N...
  • Karnataka High Court temporarily restrains German company from exploiting trade secrets of Homag India
    Image from here In an interesting judgment dated 10th October, 2012 the Karnataka High Court, sitting at Bangalore, has passed an interim in...

Categories

  • 126 (1)
  • 3(d) (4)
  • 3(f) (1)
  • 3(i) (1)
  • 3(k) (2)
  • Academic Writing (1)
  • access (10)
  • access to food (1)
  • access to health (3)
  • AIA (1)
  • AIDS/HIV (3)
  • Antitrust (2)
  • Bajaj v LML (1)
  • Basmati Row (2)
  • Biological Diversity (5)
  • Biologics (2)
  • biopiracy (4)
  • biotech (7)
  • Bollywood (25)
  • Broadcasters Rights (5)
  • Budget (1)
  • business method patent (2)
  • Call for papers (2)
  • Cipla (2)
  • Comparative Advertising (4)
  • Competition law (8)
  • Compulsory Licensing (27)
  • condonation of delay (1)
  • Conference (4)
  • Constitution (12)
  • Contracts (1)
  • Controller's decisions (8)
  • Copyright (112)
  • Copyright Amendment Bill 2010 (23)
  • copyright board (4)
  • Copyright Exceptions (6)
  • copyright office (1)
  • Copyright Rules (2013) (5)
  • Copyright Societies (9)
  • Counterfeiting (1)
  • creativity (1)
  • Cross Retaliation (1)
  • csir (4)
  • d (1)
  • D.U. Photocopy Case (16)
  • Darjeeling Tea (3)
  • Data Exclusivity (2)
  • Database (1)
  • DCGI (2)
  • decompilation (2)
  • defamation (9)
  • Designs (3)
  • Designs Act (3)
  • Differential Pricing (2)
  • Dilution (1)
  • Disabilities (3)
  • Disability (2)
  • DMCA (2)
  • Doha Declaration (1)
  • Domain Names (2)
  • Draft Policy of the Indian Government (2)
  • DRM (1)
  • Drug Regulation (7)
  • education (12)
  • Enercon (1)
  • Enforcement (1)
  • EU (2)
  • ex parte (2)
  • exhaustion (3)
  • Exhaustion of Rights (2)
  • Fair Dealing (8)
  • Fair Use (11)
  • Federal Circuit (1)
  • Fees (3)
  • FICCI (7)
  • FRAND (2)
  • free trade agreement (3)
  • FTA (3)
  • G.I. Registry (4)
  • gene sequences (3)
  • Generic medicine (4)
  • Geographical Indication (14)
  • Gilead (1)
  • Glenmark (5)
  • Gopika (34)
  • Guest post (11)
  • guidelines (1)
  • GWU-CII (1)
  • Herceptin (1)
  • hot news (3)
  • ICANN (1)
  • incremental innovation (1)
  • independence (1)
  • india (5)
  • Indian Government (1)
  • Indian patent litigation (27)
  • Indian Pharma (35)
  • Injunction (10)
  • Innovation (7)
  • INTA (1)
  • Intermediaries (10)
  • internet (11)
  • Internet Access Providers (IAPs) (5)
  • Internet Censorship (7)
  • IP scholarship (3)
  • IP aware (4)
  • IP Course (3)
  • IP Education (1)
  • IP Policy (11)
  • IP update (4)
  • ip writing competition (1)
  • IPAB (34)
  • ipchair (1)
  • IPO (1)
  • IPRS (5)
  • IT Act (1)
  • Journal (2)
  • judicial independence (3)
  • Jurisdiction (1)
  • Kruttika (4)
  • Legal Education (3)
  • Legal Research Tools (1)
  • Legal Scholarship (2)
  • library (2)
  • Licensing (7)
  • Madhulika (20)
  • mathematical methods (1)
  • Media law (3)
  • medical method (1)
  • Merck (4)
  • mhrd ip chair (1)
  • Microsoft (3)
  • Middle Path (1)
  • Moral Rights (2)
  • Movies (18)
  • musical work (2)
  • nanotechnology (1)
  • Natco (3)
  • natco defamation suit (5)
  • natco vs bayer (4)
  • need for transparency (1)
  • Novartis (8)
  • Novartis patent case in India (11)
  • NPEs (2)
  • nujs (1)
  • NUJS Conference (2)
  • Obituary (1)
  • obviousness (7)
  • Off-Topic (2)
  • online course (4)
  • Open Access (6)
  • Open Source (2)
  • Opposition (3)
  • Parallel Imports (4)
  • Parliament (1)
  • passing off (5)
  • Patent (52)
  • Patent act (10)
  • patent agent (5)
  • patent agent exam (9)
  • patent agent exam qualifications (3)
  • patent infringement (5)
  • Patent Licensing (2)
  • Patent litigation (2)
  • Patent Office (19)
  • patent pool (3)
  • Patent Prosecution (7)
  • Patent rules (2)
  • Patent Strategies (8)
  • Patents (9)
  • pegasus (1)
  • Personality Rights (1)
  • Pfizer (1)
  • Pharma (18)
  • Piracy (5)
  • plagiarism (3)
  • Plant Variety Protection (2)
  • post grant (1)
  • Prashant (2)
  • Preventive Detention (1)
  • Price Control (6)
  • prior publication (1)
  • Privacy (3)
  • Prizes (1)
  • public health (3)
  • Public Interest (4)
  • Publicity Rights (4)
  • Publishing (3)
  • radio (2)
  • Rajiv (18)
  • Rectification Petition (2)
  • Rejection (1)
  • research (3)
  • reverse engineering (2)
  • revocation (4)
  • rip (1)
  • Roche (2)
  • Roche vs Cipla (1)
  • Royalty (2)
  • RTI (2)
  • Scholarship (4)
  • section 16 (1)
  • Section 3(d) (7)
  • section 8 (6)
  • shamnad (11)
  • Shan Kohli (4)
  • Shouvik Kumar Guha (30)
  • Smartphones/Tablets (2)
  • Social Innovation (1)
  • Software (10)
  • software enforcement (3)
  • software patent (3)
  • Special 301 Report (1)
  • Spicy Tidbits (6)
  • spicyip (1)
  • SpicyIP Accolades (1)
  • SpicyIP Announcements (9)
  • SpicyIP Case (1)
  • SpicyIP Cases (3)
  • spicyip commiseration (1)
  • SpicyIP Events (11)
  • SpicyIP Fellowship (5)
  • SpicyIP Guest Series (22)
  • SpicyIP Interview (2)
  • SpicyIP Jobs (4)
  • SpicyIP Jobs/General (2)
  • SpicyIP Review (1)
  • SpicyIP Tidbits (11)
  • SpicyIP Weekly Review (27)
  • Statutory Licensing (1)
  • STI Policy 2013 (4)
  • Sugen (3)
  • Supreme Court of India (5)
  • Swaraj (19)
  • Tarnishment (1)
  • Technology (6)
  • Technology Transfer (5)
  • TKDL (5)
  • TPP (1)
  • trade (4)
  • Trade Secret Protection (1)
  • Trademark (59)
  • Trademark dilution (1)
  • Trademark Registry (9)
  • Traditional Knowledge (7)
  • Transparency (5)
  • treaty (1)
  • trial (1)
  • tribunals (2)
  • TRIPS (11)
  • UK (3)
  • unfair competition (5)
  • UNFCCC (1)
  • Universities Research and Innovation Bill (2)
  • US (1)
  • US Patent Reform (1)
  • US Supreme Court (3)
  • viva (3)
  • WIPO (5)
  • Working a Patent (2)
  • Workshop (4)
  • writ (1)
  • WTO (1)

Blog Archive

  • ▼  2013 (364)
    • ►  September (13)
    • ►  August (41)
    • ►  July (36)
    • ►  June (36)
    • ►  May (32)
    • ►  April (51)
    • ►  March (66)
    • ▼  February (40)
      • Off-Topic: Call for Papers from the Journal of Tel...
      • Budget 2013-14: What’s in stock for IP and innovat...
      • LDCs seek indefinite extension of transition perio...
      • Madras High Court judgment gives a boost to unauth...
      • SpicyIP Event: MIP India IP and Innovation Forum
      • National Innovation Foundation: Boosting Frugal Te...
      • SpicyIP Weekly Review (February Week 4)
      • SpicyIP Tidbit: Retraction Watch posts restored
      • Revisiting the Trans Pacific partnership agreement
      • The Sugen v. Cipla post-grant opposition: The lost...
      • Legality of trademark protection for deities in th...
      • Guest Post: The complex problem of developing mode...
      • SpicyIP Weekly Review- ( February Week 3)
      • Blocking (Counting) your Chickens before they hatc...
      • Accessibility of public libraries to persons with ...
      • The ‘Global’ Fund being criticized
      • Spicy IP Tidbit: Indian patent office puts an end ...
      • The G.I. Registry digitizes all G.I. records: Tran...
      • Dorling Kindersley v. Sanguine Technical Publishers
      • BMS Hepatitis Patent Invalidated: A Viral Effect f...
      • Patent prosecution highway: A potential game chang...
      • SpicyIP Event: Pharma IPR 2013
      • Patent Office finally takes Form 27s seriously
      • SpicyIP Weekly Review- (February Week 2)
      • Why aren’t there any takers for compulsory licenses?
      • The 19 year war- Financial Times Ltd. v Times Publ...
      • RetractionWatch fiasco: Manipulation of DMCA notic...
      • IPAB directs IPO to accept national phase patent a...
      • SpicyIP Events: MIP's 2nd Annual India IP and Inno...
      • New Unitary Patent System For Europe
      • Is there a need to break up the cartels in the rad...
      • Jailbreaking Sony Playstations To Be Illegal in In...
      • Is the suit again the Registrar of Copyright maint...
      • Déjà vu for Akhtar – nightmare before Barasat Cour...
      • Faking it! Indian Companies using IKEA’s trademarks
      • Latest In: Delhi HC bars Bisleri from using brand ...
      • Part II: Digitization- Growth trends of the Film a...
      • Part I: Digitization of content: a comparative ana...
      • Patent office notifies the next patent agent exami...
      • IPAB revokes several claims of yet another patent ...
    • ►  January (49)
  • ►  2012 (131)
    • ►  December (29)
    • ►  November (42)
    • ►  October (50)
    • ►  September (10)
Powered by Blogger.